Form 6-K IceCure Medical Ltd. For: Feb 09

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of February 2023

 

Commission file number: 001-40753

 

ICECURE MEDICAL LTD.

(Translation of registrant’s name into English)

 

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

☒ Form 20-F ☐ Form 40-F

 

 

 

CONTENTS

 

On February 9, 2023, IceCure Medical Ltd. (the “Company”) issued a press release titled: “IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights,” a copy of which is furnished as Exhibit 99.1 with this Report of Foreign Private Issuer on Form 6-K (the “Report”).

 

The first, second, third, ninth and tenth paragraphs and section titled “Forward Looking Statements” in the press release furnished herewith are incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration No. 333-258660 and Registration No. 333-267272) and Form S-8 (Registration No. 333-262620 and Registration No. 333-264578), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

Exhibit No.
99.1		Press release titled: “IceCure Medical Announces Preliminary Unaudited 2022 Year-End Financial Results & Recent Operational Highlights.”

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	IceCure Medical Ltd.
Date: February 9, 2023	By:	/s/ Eyal Shamir
		Name:	Eyal Shamir
		Title:	Chief Executive Officer

 

 

2

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE TITLED: "ICECURE MEDICAL ANNOUNCES PRELIMINARY UNAUDITED 2022 YEAR-END FINANCIAL RESULTS & RECENT OPERATIONAL HIGHLIGHTS."

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Pinnacle Financial Partners Announces 1Q24 Dividend
• Timberland Bancorp Reports Second Fiscal Quarter Net Income of $5.71 Million
• Cantaloupe, Inc. to Report Third Quarter Fiscal Year 2024 Results on May 9, 2024